Evercore ISI started coverage on shares of Stealth BioTherapeutics (NASDAQ:MITO) in a research note released on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $35.00 target price on the stock.
Separately, BMO Capital Markets started coverage on shares of Stealth BioTherapeutics in a research report on Tuesday. They set an outperform rating and a $29.00 price target on the stock.
Shares of MITO stock opened at $14.72 on Tuesday. Stealth BioTherapeutics has a twelve month low of $11.11 and a twelve month high of $20.99.
Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.
See Also: Gap Up Stocks
Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.